Cognitive function drug proves beneficial for patients with brain cancer

(Medical Xpress)—Whole-brain radiotherapy (WBRT) proves to be a positive therapeutic and survival tool in the treatment of brain tumors in adults, but the effect of WBRT on long-term brain function and performance is a major concern. Because of this, researchers at Emory's Nell Hodgson Woodruff School of Nursing and the Winship Cancer Institute conducted a study that highlighted positive outcomes in long-term cognitive function due to the use of the cognitive drug Memantine.

Deborah Watkins-Bruner, PhD, RN, professor at the Nell Hodgson Woodruff School of Nursing and associate director of cancer outcomes at Winship Cancer Institute at Emory, was part of a team of researchers who selected 508 eligible adult WBRT patients diagnosed with brain cancer. Participants were randomly selected to receive placebo or Memantine within three days of their initial WBRT and for 24 weeks in graduated doses.

A series of cognitive function tests was performed after the start of the study drug for 54 weeks. All patients underwent neurologic exams, history and physical exams, performance status, brain MRI and CT and other neuropsychological evaluations and assessments.

"We were pleased that the preliminary results showed better cognitive function over time in those who took Memantine," explains Watkins-Bruner. "We specifically saw a delay in the time of and reductions in the rates of memory loss, executive function and processing-speed declines. Further exploration through ongoing trials will answer some of the questions that remain, but I believe that this is a very positive step in the prevention of ."

Complete findings of the study are available in Neuro-Oncology.

More information: neuro-oncology.oxfordjournals.… 7f-a2a7-33eaf1aa6635

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

20 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

23 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.